According to the data presented at the AACR 2024 conference, as of the data cutoff date of June 12, 2023, a total of 8 patients at a median age of 11 years diagnosed with inflammatory myofibroblastic tumor (n=2), high-grade glioma (n=3), renal cell carcinoma (n=2), and anaplastic large cell lymphoma (n=1, protocol deviation) were enrolled. Among 7 patients evaluable for efficacy, 6 had not received prior systemic therapy. Furthermore, the ALK fusion partners were KIF5C in 2 patients and TPM3, CLTC, PLEKHA7, DCTN1, and HNRNPA3 in 1 patient each. Apart from that, the median treatment duration was 12 months, and no dose-limiting toxicities were reported.
Investigators...
